ArticleThe oncologist2019

A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.

Daniel Reinhorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.